Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor

@article{Baral2006ExperimentalTO,
  title={Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor},
  author={Toya Nath Baral and Stefan Magez and Beno{\^i}t Stijlemans and Katja Conrath and Benoit Vanhollebeke and E. Pays and Serge Muyldermans and Patrick de Baetselier},
  journal={Nature Medicine},
  year={2006},
  volume={12},
  pages={580-584}
}
High systemic drug toxicity and increasing prevalence of drug resistance hampers efficient treatment of human African trypanosomiasis (HAT). Hence, development of new highly specific trypanocidal drugs is necessary. Normal human serum (NHS) contains apolipoprotein L-I (apoL-I), which lyses African trypanosomes except resistant forms such as Trypanosoma brucei rhodesiense. T. b. rhodesiense expresses the apoL-I–neutralizing serum resistance–associated (SRA) protein, endowing this parasite with… CONTINUE READING
7 Citations
33 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 33 references

TNF-a mediates the development of anaemia in a murine Trypanosoma brucei rhodesiense infection, but not the anaemia associated with a murine Trypanosoma congolense infection

  • J Naessens
  • Clin. Exp. Immunol
  • 2005

Similar Papers

Loading similar papers…